Plasma thrombin-activatable fibrinolysis inhibitor levels are not associated with glucose intolerance and subclinical atherosclerosis in women with previous gestational diabetes

Clin Appl Thromb Hemost. Nov-Dec 2011;17(6):E224-30. doi: 10.1177/1076029610397753. Epub 2011 Mar 14.


We aimed to determine plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in women with previous gestational diabetes mellitus (GDM) and to evaluate the possible association of plasma TAFI with glucose intolerance and markers of subclinical atherosclerosis. This cross-sectional study was performed in 111 women with previous GDM and 60 controls. Glucose intolerance was evaluated. Homeostasis model assessment score was calculated. Circulating lipids, interleukin-6, matrix metalloproteinase-1, fibrinogen, plasminogen activator inhibitor-1, and TAFI antigen levels were assayed. Carotid intima media thickness (IMT) was measured. Women with previous GDM had increased levels of atherosclerosis markers and carotid IMT. On the other hand, plasma TAFI antigen levels were similar (P = .395). Thrombin-activatable fibrinolysis inhibitor was not associated with the indices of insulin resistance, glucose intolerance, markers of atherosclerosis, and carotid IMT. Our data demonstrated that plasma TAFI was not altered in women with previous GDM. TAFI was not associated with glucose intolerance and subclinical atherosclerosis.

MeSH terms

  • Adult
  • Atherosclerosis / blood*
  • Carboxypeptidase B2 / blood*
  • Carotid Intima-Media Thickness
  • Cross-Sectional Studies
  • Diabetes, Gestational / blood*
  • Female
  • Fibrinolysis
  • Glucose Intolerance / blood*
  • Humans
  • Pregnancy
  • Pregnancy Complications, Cardiovascular / blood*


  • Carboxypeptidase B2